1/28
Looks like no tags are added yet.
Hormones can stimulate receptor-mediated cell proliferation, increasing opportunities for mutations.
Oestrogen receptor activation stimulates proliferation
ERK/PI3K growth pathways may be activated
reactive oestrogen metabolites can damage DNA
altered DNA repair may allow mutations to accumulate.
so basically either causes proliferation or DNA damage
Early menarche (earlier getting period), late menopause, postmenopausal obesity and some HRT exposures increase lifetime oestrogen exposure.
oestrogen-only stimulates endometrial proliferation and increases cancer risk in people with a uterus.
Adding progestogen protects the endometrium by opposing this stimulation.
Hormones may stimulate residual or recurrent hormone-sensitive breast cancer.
Non-hormonal alternatives are generally preferred, with specialist assessment of individual circumstances.
Current or recent use is associated with a small increased breast cancer risk; longer use can increase cervical cancer risk.
It reduces ovarian and endometrial cancer risk, with protection that can persist after stopping.
Oestrogen binds the oestrogen receptor, activating gene transcription and growth signalling that promote tumour-cell proliferation.
Oestrogen receptor blockade with tamoxifen,
reduced oestrogen synthesis using aromatase inhibitors such as anastrozole, letrozole and exemestane.
Tamoxifen is a selective oestrogen receptor modulator (SERM).
In breast tissue it antagonises the oestrogen receptor, reducing oestrogen-dependent gene expression and proliferation.
Name three aromatase inhibitors and their MOA?
Anastrozole, letrozole and exemestane.
They inhibit aromatase, reducing conversion of androgens into oestrogens
limits stimulation of ER-positive breast cancer.
After menopause, peripheral aromatase activity is a major source of oestrogen.
Before menopause, ovarian oestrogen production persists, so aromatase inhibitors wouldn’t be able to target this oestrogen → wouldnt be effective enough
Tamoxifen blocks oestrogen receptor signalling and can be used before or after menopause; important adverse effects include hot flushes and thromboembolism.
Aromatase inhibitors lower oestrogen synthesis, used after menopause, and can cause joint pain, bone loss and fractures.
ER is oestrogen receptor
PR is progesterone receptor
HER2 is human epidermal growth factor receptor 2
ER-positive disease may respond to endocrine therapy.
HER2-positive disease may respond to HER2-targeted treatment such as trastuzumab.
Triple-negative disease lacks ER, PR and HER2, so these receptor-targeted treatments are not appropriate.
HER2 is a cell-surface growth-signalling receptor.
Overexpression or amplification increases growth and survival signalling, contributing to tumour proliferation.
Trastuzumab is a chimeric monoclonal antibody (part human part mouse)
It interferes with HER2-associated signalling and recruits immune mechanisms, including antibody-dependent cell-mediated cytotoxicity.
An antibody binds an antigen on a cancer cell. Immune effector cells recognise the antibody-coated cell and attack or destroy it.
Trastuzumab can promote ADCC against HER2-positive cancer cells.
It is a protein antibody that would be degraded in the digestive tract, so it is administered by injection or infusion.
risks - infusion reactions and cardiac toxicity.
TNBC lacks ER, PR and HER2.
Endocrine therapies and conventional HER2-directed therapies do not target it effectively.
It can be aggressive and often requires chemotherapy and surgery, with other treatments where appropriate.
Pembrolizumab is a PD-1-blocking immunotherapy
olaparib and talazoparib are PARP inhibitors for selected BRCA-associated disease
Testosterone is converted by 5α-reductase to the more potent androgen DHT.
Androgens bind to the androgen receptor, promoting transcription of growth and survival genes in prostate cells.
Androgen deprivation therapy (ADT) reduces testicular testosterone production
abiraterone inhibits androgen biosynthesis
enzalutamide inhibits androgen receptor signalling.
Treatment that lowers androgen stimulation of prostate cancer, commonly through GnRH-based medical treatment or surgical orchidectomy.
It can initially suppress hormone-sensitive tumour growth.
Abiraterone inhibits CYP17A1, reducing androgen synthesis in the testes, adrenal glands and tumour tissue.
This lowers androgen receptor stimulation and slows prostate cancer growth.
Enzalutamide inhibits the androgen receptor.
It interferes with androgen-driven receptor activation, nuclear translocation and DNA-mediated transcription, reducing prostate cancer growth signalling.
Abiraterone reduces androgen production by inhibiting CYP17A1.
Enzalutamide blocks androgen receptor signalling.
What are the main stages of prostate cancer?
Localised prostate cancer is confined to the prostate.
Metastatic hormone-sensitive disease has spread but responds to androgen suppression
. Castration-resistant disease progresses despite castrate testosterone levels (low levels of testosterone still allow cancer to grow)
Prostate cancer that progresses despite testosterone being reduced to castrate levels.
Tumour cells adapt through mechanisms such as increased androgen receptor signalling or local androgen production; they may still respond to further androgen-targeted drugs.
Low testosterone can cause hot flushes, reduced libido, erectile problems, fatigue, muscle loss, weight gain, bone thinning and gynaecomastia. (feminisation)
PSA is monitored alongside clinical assessment and other investigations.